Introduction Postoperative thrombocytopenia (PTC) after aortic valve replacement by sutureless biological prosthesis (Perceval type) is described in the literature, however, its clinical relevance has not yet been established. • Primary objective: Description of platelet count after biological aortic valve replacement with Perceval® and Trifecta types. • Secondary objective: To compare need of transfusions (red blood cells (RBCs), Platelets, fibrinogen), re-explorations for bleeding in the first 48 hours, ICU stay, hospital stay and mortality at 30 days. Methods A retrospective comparative observational cohort study was conducted using data extracted from digital medical records, including data obtained by intraoperative thromboelastography (TEG) of patients undergoing aortic valve replacement with biological prosthesis Perceval and Trifecta, at our hospital. We performed consecutive non-randomized sampling from January 2018 to December 2018, including a total of 74 patients. 32 of them received Perceval®, 42 received Trifecta . Results We found a PTC after biological valve replacement that in both groups becomes severe, being in the Perceval group minimum values of 20 × 103 on the 4th postoperative day, while in the Trifecta group it was 50 × 103 also on the 4th postoperative day. We found no statistically significant differences in preoperative or postoperative platelet count except at hospital discharge, with Perceval presenting lower platelet count figures (median 133 × 103 interquartile range 108 - 203 × 103) than Trifecta® (median 230 × 103, interquartile range 167 - 220 × 103), (p = 0.018). Intraoperatively, we found statistically significant differences in the number of (RBCs) transfused, as follows in the Perceval group (mean: 1.06) versus Trifecta (mean: 0.31), (p = 0.005) We found no statistically significant differences in intra- or postoperative transfusion of blood products (platelets, fibrinogen), as well as in the need for re-explorations due to bleeding, ICU stay, hospital stay or mortality at 30 days. Discussion Biological valve replacement with Perceval and Trifecta causes postoperative thrombocytopenia, which, although it becomes severe on the fourth postoperative day in both groups, does not persist at hospital discharge. In our sample has not conditioned greater morbidity or mortality in patients. Larger sample studies will be necessary to corroborate the statistical significance.